Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study
American Journal of Neuroradiology · 2024-05 · 45 (5) · 592-598
DOI: 10.3174/ajnr.a8163 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Neuroradiology, online erschienen am 07.03.2024. Verfasst von Sophia Hohenstatt und 11 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Neuroradiology (S.H., J.J., M.B., D.F.V., M.A.M.), Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Intracranial Aneurysm, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Clopidogrel. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: The optimal antiplatelet regimen after flow diverter treatment of cerebral aneurysms is still a matter of debate. A single antiplatelet therapy might be advantageous in determined clinical scenarios. This study evaluated the efficacy and safety of prasugrel single antiplatelet therapy versus aspirin and clopidogrel dual antiplatelet therapy. MATERIALS AND METHODS: We performed a post hoc analysis of 4 retrospective multicenter studies including ruptured and unruptured aneurysms treated with flow diversion using either prasugrel single antiplatelet therapy or dual antiplatelet therapy. Primary end points were the occurrence of any kind of procedure- or device-related thromboembolic complications and complete aneurysm occlusion at the latest radiologic follow-up (mean, 18 months). Dichotomized comparisons of outcomes were performed between single antiplatelet therapy and dual antiplatelet therapy. Additionally, the influence of various patient- and aneurysm-related variables on the occurrence of thromboembolic complications was investigated using multivariable backward logistic regression. RESULTS: A total of 222 patients with 251 aneurysms were included, 90 (40.5%) in the single antiplatelet therapy and 132 (59.5%) in the dual antiplatelet therapy group. The primary outcome-procedure- or device-related thromboembolic complications-occurred in 6 patients (6.6%) of the single antiplatelet therapy and in 12 patients (9.0%) of the dual antiplatelet therapy group (P = .62; OR, 0.712; 95% CI, 0.260-1.930). The primary treatment efficacy end point was reached in 82 patients (80.4%) of the single antiplatelet therapy and in 115 patients (78.2%) of the dual antiplatelet therapy group (P = .752; OR, 1.141; 95% CI, 0.599-2.101). Logistic regression showed that non-surface-modified flow diverters (P = .014) and fusiform aneurysm morphology (P = .004) significantly increased the probability of thromboembolic complications. CONCLUSIONS: Prasugrel single antiplatelet therapy after flow diverter treatment may be as safe and effective as dual antiplatelet therapy and could, therefore, be a valid alternative in selected patients. Further prospective comparative studies are required to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Neuroradiology (S.H., J.J., M.B., D.F.V., M.A.M.), Heidelberg University Hospital, Heidelberg, Germany.
- Interventional Neuroradiology Section (I.S., H.S.C.), Koru and Bayindir Private Hospitals, Ankara, Turkey.
- Department of Neuroradiology (N.K., CI.), Cerrahpasa Medical Faculty, Istanbul, Turkey.
- Department of Neuroradiology (H.L.), University of Erlangen-Nuremberg, Erlangen, Germany.
- Department of Clinical Neurosciences (J.D.), Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
- Department of Interventional Radiology (R.R.), Turku University Hospital, Turku, Finland.
ORCID-Profile: Sophia Hohenstatt, Işıl Saatci, Jessica Jesser, H Saruhan Çekirge, Naci Koçer, Civan Islak, Hannes Lücking, Johannes DuPlessis, Riitta Rautio, Martin Bendszus, Dominik F Vollherbst, Markus A Möhlenbruch
Zitieren
APA
Hohenstatt, S., Saatci, I., Jesser, J., Çekirge, H. S., Koçer, N., Islak, C., Lücking, H., DuPlessis, J., Rautio, R., Bendszus, M., Vollherbst, D. F., & Möhlenbruch, M. A. (2024). Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study. American Journal of Neuroradiology, 45(5), 592-598. https://doi.org/10.3174/ajnr.a8163
Vancouver
Hohenstatt S, Saatci I, Jesser J, Çekirge HS, Koçer N, Islak C, et al. Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study. American Journal of Neuroradiology. 2024;45(5):592-598. doi:10.3174/ajnr.a8163
BibTeX
@article{Hohenstatt2024,
author = {Hohenstatt, Sophia and Saatci, Işıl and Jesser, Jessica and Çekirge, H Saruhan and Koçer, Naci and Islak, Civan and Lücking, Hannes and DuPlessis, Johannes and Rautio, Riitta and Bendszus, Martin and Vollherbst, Dominik F and Möhlenbruch, Markus A},
title = {Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study},
journal = {American Journal of Neuroradiology},
year = {2024},
volume = {45},
number = {5},
pages = {592--598},
doi = {10.3174/ajnr.a8163}
}
EUVIMED